Shearman & Sterling represented Citigroup, Goldman Sachs and Morgan Stanley as joint bookrunning managers and representatives of the several underwriters in connection with Amgen’s registered offering of $1.5 billion of investment grade notes, consisting of $900 million of 3.45% senior notes due 2020 and $600 million of 4.95% senior notes due 2041
.
Amgen is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.
The following Shearman & Sterling team advised the underwriters in the transaction: partners John Wilson (San Francisco-Capital Markets), Mark Hyland (San Francisco-Capital Markets) and Heather Kafele (Washington, DC-Antitrust); counsels Jung-Kyu McCann (Menlo Park-Capital Markets) and Adam Noah (San Francisco-Litigation); and associates Phillip Monk (Menlo Park-Capital Markets), Emily Griffen (San Francisco-Litigation); Zheng Bao (Menlo Park-Intellectual Property Transactions), Eileen O’Pray (Menlo Park-Tax), Anil Kalia (Menlo Park-Tax) and Frances Ma (New York-Executive Compensation & Employee Benefits).
